Emyria has today announced the opening of a new clinical facility – The Empax Centre – dedicated to the delivery and development of new treatments for mental health.
The purpose-built centre combines patient-centred design and cutting-edge technology, and increases Emyria’s clinical service capacity to support the treatment and research of complex mental health conditions such as Post-Traumatic Stress Disorder (PTSD).
Led by some of Australia’s first authorised MDMA-AT prescribers, the Empax Centre has a supporting team of over 14 clinicians specially trained in psychedelic-assisted therapy, and features advanced technology for superior patient care and data-driven research.
Emyria CEO and MD, Dr. Michael Winlo, commented:
“The Empax Centre demonstrates Emyria’s commitment to lead the way in mental health innovation within the regulatory frameworks set by the TGA.
“Our extensive research and development efforts, particularly in MDMA-assisted therapy for PTSD, have shaped our strategic approach towards scalability and profitability – essential for the widespread adoption and success of these innovative treatments.
“This new facility not only signifies our commitment to improving mental health care but also highlights our firm belief in the transformative potential of our treatments and research.”
Click here to read the ASX release.